{"id":389801,"date":"2022-07-05T00:00:00","date_gmt":"2022-07-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0017-2022-biopharma-psoriasis-access-reimbursement-us-2022\/"},"modified":"2026-03-31T10:39:01","modified_gmt":"2026-03-31T10:39:01","slug":"acreim0017-2022-biopharma-psoriasis-access-reimbursement-us-2022","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/acreim0017-2022-biopharma-psoriasis-access-reimbursement-us-2022\/","title":{"rendered":"Psoriasis | Access &#038; Reimbursement | US | 2022"},"content":{"rendered":"<p>Janssen\u2019s interleukin (IL)-12\/23 inhibitor Stelara, AbbVie\u2019s tumor necrosis factor-alpha (TNF-\u03b1) inhibitor Humira, and Novartis\u2019s IL-17A inhibitor Cosentyx lead the U.S. psoriasis biologics market, but the approval of novel, more-effective therapies has started changing the landscape as newer biologics gain greater acceptance from treating physicians. Eli Lilly\u2019s IL-17 inhibitor Taltz and Amgen\u2019s oral PDE-4 inhibitor Otezla have successfully carved out space in the treatment algorithm. More-effective biologics\u2014AbbVie\u2019s Skyrizi and Janssen\u2019s Tremfya\u2014and emerging therapies in the late-phase pipeline are threatening the dominance of earlier-to-market biologics. Given the recent entry of infliximab biosimilars, along with the development of another IL-17 A\/F dual inhibitor, an oral TYK2 inhibitor, and two novel topical therapies, marketers of psoriasis therapies must learn how to navigate this increasingly competitive market.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>Among commercially insured psoriasis patients, what percentage receive newer biological agents, and which biologics \/ Otezla do physicians perceive to perform the best on specific clinical and market access factors?<\/li>\n<li>How do payers cover biosimilar versions of infliximab (Pfizer\u2019s Inflectra, Merck\u2019s Renflexis, and Amgen\u2019s Avsola), and how do physicians expect to prescribe these biosimilars?<\/li>\n<li>What are physician perceptions of emerging therapies such as bimekizumab, Remsima (SC), deucravacitinib, and emerging nonsteroidal topical agents with novel mechanisms of action? How do payers anticipate covering these agents?<\/li>\n<li>For psoriasis drugs with similar efficacy and safety, what economic factors most influence favorable coverage in MCOs\u2019 largest fully insured plans?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION<\/strong><\/p>\n<p><em>U.S. Access &#038; Reimbursement<\/em> provides integrated brand- and disease-level insight on reimbursement dynamics and the impact of U.S. payer policy on physician prescribing behavior in the market access environment, including up-to-date analysis of drug coverage and restriction policies and payer and prescriber perspectives on key marketed drugs and receptivity to emerging therapies.<\/p>\n<p><strong>Key drugs: <\/strong>Humira, Enbrel, Remicade, Inflectra, Renflexis, Avsola, Cimzia, Stelara, Otezla, Cosentyx, Taltz, Siliq, Tremfya, Ilumya, Skyrizi, Remsima (SC), bimekizumab, deucravacitinib, roflumilast (topical), tapinarof<\/p>\n<p><strong>Key companies: <\/strong>AbbVie, Amgen, Arcutis, Bristol-Myers Squibb, Dermavant, Eli Lilly, Janssen, Merck, Pfizer, Novartis, UCB.<\/p>\n","protected":false},"template":"","class_list":["post-389801","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-psoriasis","biopharma-geography-us","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389801","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389801\/revisions"}],"predecessor-version":[{"id":576228,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389801\/revisions\/576228"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389801"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}